
1. antimicrob agents chemother. 2017 nov 22;61(12). pii: e00759-17. doi:
10.1128/aac.00759-17. print 2017 dec.

sustained ex vivo susceptibility plasmodium falciparum artemisinin
derivatives increasing tolerance artemisinin combination therapy partner
quinolines gambia.

amambua-ngwa a(1), okebe j(2), mbye h(2), ceesay s(2), el-fatouri f(2), joof
f(2), nyang h(2), janha r(2), affara m(2), ahmad a(2), kolly o(3), nwakanma d(2),
d'alessandro u(2)(4).

author information: 
(1)medical research council unit gambia, fajara, gambia angwa@mrc.gm.
(2)medical research council unit gambia, fajara, gambia.
(3)national malaria control programme, banjul, gambia.
(4)london school hygiene tropical medicine, london, united kingdom.

antimalarial interventions yielded significant decline malaria
prevalence gambia, artemether-lumefantrine (al) used a
first-line antimalarial decade. clinical plasmodium falciparum isolates
collected 2012 2015 analyzed ex vivo antimalarial susceptibility
and genotyped drug resistance markers (pfcrt k76t, pfmdr1 codons 86, 184, and
1246, pfk13) microsatellite variation. additionally, allele frequencies
of single nucleotide polymorphisms (snps) drug resistance-associated
genes compared genomic sequence data sets 2008 (n = 79) 2014
(n = 168). artemisinin resistance-associated pfk13 mutation found, and
only 4% isolates tested 2015 showed significant growth exposure
to dihydroartemisinin. conversely, 50% inhibitory concentrations (ic50s) of
amodiaquine lumefantrine increased within period. pfcrt 76t pfmdr1
184f mutants remained prevalence 80%. pfcrt 76t positively
associated higher ic50s chloroquine. pfmdr1 nyd increased frequency
between 2012 2015 due lumefantrine selection. tnyd (pfcrt 76t and
pfmdr1 nyd wild-type haplotype) also increased frequency following al
implementation 2008. results suggest selection pfcrt pfmdr1
genotypes enable tolerance lumefantrine. increased tolerance to
lumefantrine calls sustained chemotherapeutic monitoring gambia to
minimize complete artemisinin combination therapy (act) failure future.

copyright Â© 2017 amambua-ngwa et al.

doi: 10.1128/aac.00759-17 
pmcid: pmc5700332
pmid: 28971859  [indexed medline]

